Larimar Therapeutics (LRMR)
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide...
- Open
- 3.820
- High
- 3.850
- Low
- 3.790
- Prev. Close
- 3.830
- Volume
- 391.99K
- Turnover
- 1.50M
- Avg Price
- 3.828
- Bid/Ask Ratio
- --
- Amplitude
- 1.57%
- 52wk High
- 6.420
- Volume Ratio
- 0.33
- Turnover Ratio
- 0.68%
Larimar Therapeutics Analyst Rating
View moreForecast & Rating
Aug 7, 2026Price forecast
$14.30273.37%
Forecast & RatingStrong buy
11analysts
- Strong buy81.82%
- Buy18.18%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 26 at 10:18 AM
Putprop extends Dobsonville lease with Larimar at monthly rent of R 314,608
- Market Beat · Aug 13 at 09:12 AM
Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR
- Market Beat · Aug 6 at 07:11 AM
Larimar Therapeutics (LRMR) to Announce Earnings on Thursday
- Tip Ranks · Aug 5 at 06:02 AM
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
- TradingView · Aug 4 at 11:21 AM
Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary
- PUBT · Aug 4 at 11:07 AM
Larimar Therapeutics Q2 net loss widens to $32.78 million; R&D expenses rise to $28 million
